School of Medicine, Nankai University, Tianjin, China.
Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
Horm Metab Res. 2022 Mar;54(3):145-152. doi: 10.1055/a-1749-5716. Epub 2022 Mar 11.
Interferon (IFN) is a broad-spectrum antiviral agent that activates cell surface receptors and causes cells to produce antiviral proteins, inhibiting viral replication. Interferon use has long been associated with diabetes. The PubMed database was searched for articles related to diabetes and interferon from March 30, 2020. Patients were divided into type 1 diabetes group and type 2 diabetes group. We reviewed the relevant literature to compare interferon-associated T1D and interferon-associated T2D differences. Interferon treatment shortened the incubation period of T2D and changed the original T2D to T1D. The onset of interferon-associated T1D required longer periods of IFN treatment than interferon-associated T2D, and the interferon-associated T1D group had higher GADA positive rates, lower BMI, lower fasting blood glucose, and greater insulin dependence (p<0.05). More patients in the T1D group were positive for HLA-DRB104, DRB103, DRB109, DRB114, HLA-DQB104, HLA-DQB102, HLA-DQB103, and HLA-DQB105. The combined detection of GAD antibodies and HLA alleles may be an effective method to predict the incidence of T1D after IFN treatment.
干扰素（IFN）是一种广谱抗病毒药物，可激活细胞表面受体并促使细胞产生抗病毒蛋白，从而抑制病毒复制。干扰素的使用长期以来一直与糖尿病有关。从 2020 年 3 月 30 日起，我们在 PubMed 数据库中搜索了与糖尿病和干扰素相关的文章。将患者分为 1 型糖尿病组和 2 型糖尿病组。我们复习了相关文献，比较了干扰素相关 1 型糖尿病和干扰素相关 2 型糖尿病的差异。干扰素治疗缩短了 2 型糖尿病的潜伏期，并使原来的 2 型糖尿病转变为 1 型糖尿病。干扰素相关 1 型糖尿病的发病需要更长时间的 IFN 治疗，且干扰素相关 1 型糖尿病组的 GADA 阳性率更高、BMI 更低、空腹血糖更低、胰岛素依赖性更强（p<0.05）。1 型糖尿病组中有更多患者 HLA-DRB104、DRB103、DRB109、DRB114、HLA-DQB104、HLA-DQB102、HLA-DQB103 和 HLA-DQB105 阳性。GAD 抗体和 HLA 等位基因的联合检测可能是预测 IFN 治疗后 1 型糖尿病发生率的有效方法。
